Abstract
Dexmedetomidine (DEX) exerts protective effects on liver function while having little effect on inflammation-related biomarkers in the early postoperative period in patients undergoing hepatectomy due to hepatocellular carcinoma (HCC).
Introduction
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality globally. While surgical resection (hepatectomy) is the gold standard for treatment, the procedure often requires temporary occlusion of hepatic blood flow, leading to ischemia-reperfusion injury (IRI). This process triggers oxidative stress and inflammatory responses that can impair liver function. Dexmedetomidine (DEX), a highly selective $\alpha_2$-receptor agonist, is widely used for sedation, but its potential clinical role in protecting the liver during human HCC surgery has remained unclear.
Methods
Researchers conducted a retrospective cohort study of 494 patients at the Eastern Hepatobiliary Surgery Hospital in Shanghai. To account for inherent biases in non-randomized data, Propensity Score Matching (PSM) was used to create two balanced groups of 107 patients each (DEX vs. DEX-free), matched across 18 clinical variables.
The primary endpoint was serum alanine transaminase (ALT) levels, a key biomarker for liver damage. Secondary endpoints included other liver function markers (AST, LDH, Albumin), inflammatory biomarkers (CRP, WBC count), and overall survival (OS).
Results
Mitigation of Liver Injury and Maintenance of Function
The study found that DEX significantly reduced markers of liver injury. After PSM, the DEX group showed significantly lower levels of ALT ($P = 0.044$) and LDH ($P = 0.046$) in the early postoperative period. Crucially, DEX also helped maintain the liver's synthetic capacity; patients in the DEX group had significantly higher serum albumin (ALB) levels before discharge ($P = 0.002$).
Inflammation and Long-term Survival
Despite the hepatoprotective effects, DEX did not appear to influence systemic inflammation. No significant differences were found in CRP or white blood cell counts between the groups. Furthermore, Kaplan–Meier analysis showed no significant difference in overall survival ($P = 0.076$), suggesting that long-term outcomes are driven more by tumor biology than perioperative sedation.
Discussion and Conclusion
This study demonstrates that DEX acts as a hepatoprotective agent during liver cancer surgery by reducing injury markers and maintaining albumin production. However, these benefits do not translate into reduced systemic inflammation or improved long-term survival.
Limitations include the study's retrospective design and single-center focus. Future multi-center prospective randomized controlled trials are needed to confirm these findings and explore the molecular mechanisms, such as the Nrf2/HO-1 or TLR4 pathways, through which DEX exerts its influence.
Summary updated